When to Use Systemic Corticosteroids for Upper Respiratory Infections
Systemic corticosteroids should NOT be routinely used for uncomplicated upper respiratory infections, with the specific exception of intranasal corticosteroids as adjunctive therapy in acute bacterial rhinosinusitis, particularly in patients with allergic rhinitis.
Evidence-Based Framework
Acute Bacterial Rhinosinusitis (ABRS)
The IDSA guideline 1 provides clear direction:
- Intranasal corticosteroids are recommended as adjunct to antibiotics in ABRS, primarily for patients with allergic rhinitis history (weak recommendation, moderate evidence)
- Systemic (oral/intramuscular) corticosteroids are NOT mentioned as recommended therapy
- Topical and oral decongestants/antihistamines are explicitly NOT recommended 1
General Upper Respiratory Infections
The evidence strongly argues against routine systemic corticosteroid use:
Key Safety Concerns:
- A large retrospective study 2 of 153,848 patients found that intramuscular corticosteroid injection for acute URI was associated with 74% increased odds of return visits within 60 days (OR: 1.74; 95% CI: 1.61-1.88)
- Despite 22.5% of patients receiving injections, there is lack of evidence for impact and safety 2
- Recent 2026 evidence 3 highlights that even short-term systemic corticosteroids carry risks of sepsis, pneumonia, gastrointestinal bleeding, acute pancreatitis, heart failure, venous thromboembolism, and fracture
Mechanism Considerations:
- NSAIDs are preferred over corticosteroids for fever and pain in early viral infections because they don't hinder immune response 4
- Corticosteroids can weaken immune response and are not recommended for pain/fever relief 4
- Both can mask serious infections, requiring clinical caution 4
Clinical Algorithm
Step 1: Diagnose the Specific Condition
- Viral URI (common cold, pharyngitis): NO systemic corticosteroids
- Acute bacterial rhinosinusitis: Consider intranasal corticosteroids only, especially if allergic rhinitis present
- Severe conditions requiring hospitalization: Different considerations apply (not routine URI)
Step 2: Patient-Specific Factors
Use intranasal corticosteroids in ABRS if:
- History of allergic rhinitis
- Already on antibiotic therapy
- Symptoms include significant nasal congestion
Avoid systemic corticosteroids if:
- Uncomplicated viral URI
- No clear bacterial superinfection
- Seeking symptom relief only (use NSAIDs instead)
Step 3: Monitor for Treatment Failure
- If symptoms worsen after 48-72 hours or fail to improve after 3-5 days on antibiotics, consider alternative antimicrobial strategy—NOT corticosteroid escalation 1
Common Pitfalls to Avoid
Do not use intramuscular corticosteroid injections for routine URI—this practice is highly prevalent (up to 49% in some clinics) but lacks evidence and increases return visits 2
Do not confuse intranasal with systemic corticosteroids—only intranasal formulations have guideline support in ABRS 1
Do not prescribe systemic corticosteroids for symptom relief—NSAIDs are superior for fever/pain without immune suppression 4
Recognize the 22.5% baseline prescription rate is inappropriate and contributes to unnecessary healthcare utilization 2
Special Populations
Pediatric patients: A Cochrane overview 5 found systemic corticosteroids safe for short-term use in specific acute respiratory conditions (croup, asthma exacerbations) but this does NOT extend to routine URI
Aviation/occupational medicine: Despite claims that corticosteroids hasten recovery 6, the increased return visit rate 2 and lack of guideline support argue against routine use even when minimizing time off duty is desired
Bottom Line
The only guideline-supported corticosteroid use in URI is intranasal formulations as adjunct to antibiotics in ABRS with allergic rhinitis 1. Systemic corticosteroids carry documented risks of increased healthcare utilization 2 and serious adverse events 3 without proven benefit in uncomplicated URI. When patients need symptomatic relief, NSAIDs are the preferred anti-inflammatory option 4.